EUVIMEDEUVIMED entdecken
Crossref

Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis

Sami Ullah iD, Martin Ursli, Uwe Fuhr, Martin Wiesholzer, Manuel Kussmann, Wolfgang Poeppl, Markus Zeitlinger, Max Taubert

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · 2023

DOI: 10.1177/08968608231167237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2023. Verfasst von Sami Ullah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Germany. Hauptthemen laut MEDLINE: Peritoneal Dialysis, Peritonitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meropenem is a second-line agent for the treatment of peritoneal dialysis-associated peritonitis (PD peritonitis), while information on pharmacokinetics (PK) of intraperitoneal (i.p.) meropenem is limited in this patient group. The objective of the present evaluation was to assess a pharmacokinetic rationale for the selection of meropenem doses in automated PD (APD) patients based on population PK modelling.

Methods

Data were available from a PK study in six patients undergoing APD who received a single 500 mg dose of meropenem intravenous or i.p. A population PK model was developed for plasma and dialysate concentrations ( n = 360) using Monolix. Monte Carlo simulations were carried out to assess the probability of achieving meropenem concentrations above minimum inhibitory concentrations (MICs) of 2 and 8 mg/L, representing susceptible and less susceptible pathogens respectively, for at least 40% of the dosing interval ( T >MIC ≥ 40%).

Results

A two-compartment model for each plasma and dialysate concentrations with one transit compartment for the transfer from plasma to dialysate fluid described the data well. An i.p. dose of 250 and 750 mg, for an MIC of 2 and 8 mg/L respectively, was sufficient to attain the pharmacokinetic/pharmacodynamic target ( T >MIC ≥ 40%) in more than 90% patients in plasma and dialysate. Additionally, the model predicted that no relevant meropenem accumulation in plasma and/or peritoneal fluid would occur with prolonged treatment.

Conclusion

Our results suggest that an i.p. dose of 750 mg daily is optimal for pathogens with an MIC 2–8 mg/L in APD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal DialysisPeritonitisHumansMeropenemAnti-Bacterial AgentsDialysis SolutionsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Automated peritoneal dialysisMonte Carlo simulationsmeropenemnon-linear mixed effects modelpopulation pharmacokineticsprobability of target attainment

Substanzen

MeropenemAnti-Bacterial AgentsDialysis Solutions

Autor:innen und Institutionen

  • Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Germany.
  • Department of Internal Medicine I, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, Austria.
  • Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Austria.
  • Department of Dermatology and Tropical Medicine, Military Medical Cluster East, Austrian Armed Forces, Vienna, Austria.
  • Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel, Austria.

ORCID-Profile: Sami Ullah

Zitieren

APA

Ullah, S., Ursli, M., Fuhr, U., Wiesholzer, M., Kussmann, M., Poeppl, W., Zeitlinger, M., & Taubert, M. (2023). Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. https://doi.org/10.1177/08968608231167237

Vancouver

Ullah S, Ursli M, Fuhr U, Wiesholzer M, Kussmann M, Poeppl W, et al. Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2023. doi:10.1177/08968608231167237

BibTeX
@article{Ullah2023,
  author = {Ullah, Sami and Ursli, Martin and Fuhr, Uwe and Wiesholzer, Martin and Kussmann, Manuel and Poeppl, Wolfgang and Zeitlinger, Markus and Taubert, Max},
  title = {Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis},
  journal = {Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis},
  year = {2023},
  doi = {10.1177/08968608231167237}
}
Kostenlos starten →